Demonstrating Adherence to Guidelines for the Treatment of Patients With Borderline Personality Disorder

被引:22
|
作者
Kolla, Nathan J. [1 ]
Links, Paul S. [1 ,2 ]
MeMain, Shelley [1 ]
Streiner, David L.
Cardish, Robert [1 ]
Cook, Michele [3 ]
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[2] St Michaels Hosp, Arthur Sommer Rotenberg Chair Suicide Studies, Toronto, ON M5B 1W8, Canada
[3] St Michaels Hosp, Suicide Studies Unit, Toronto, ON M5B 1W8, Canada
基金
加拿大健康研究院;
关键词
borderline personality disorder; psychotherapy; adherence; PSYCHOTHERAPY; THERAPY; COMPETENCE; TRIAL;
D O I
10.1177/070674370905400306
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To describe the development and implementation of General Psychiatric Management (GPM), a dynamically informed psychotherapeutic and case management approach along with symptom-targeted pharmacological interventions for the treatment of borderline personality disorder (BPD), derived from the American Psychiatric Association's (APA) guidelines for treating BPD. Method: Clinician adherence to GPM was assessed using the General Psychiatric Management Adherence Scale (GPMAS), which measured the amount of emphasis accorded to therapeutic tools and strategies during individual therapy sessions. GPMAS surveys were completed by 9 different therapists every 6 weeks during I year for 50 patients. Results: GPMAS displayed excellent internal consistency and good-to-excellent test-retest reliability. The convergence between patient- and therapist-rated sessions was excellent. Mean levels of emphasis were significantly greater for GPM interventions than prohibited ones across all time points. The mean number of prescribed psychotropic medications was 2.3, and the most frequently prescribed class of medication was antidepressants, followed by neuroleptics. Conclusions: From these results, we conclude that the clinicians were adherent to the outlined protocol and that the GPMAS is a valuable measure for demonstrating adherence to therapies based on the APA guidelines.
引用
收藏
页码:181 / 189
页数:9
相关论文
共 50 条
  • [31] Practice guideline for the treatment of patients with borderline personality disorder - Introduction
    不详
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (10): : 2 - 2
  • [32] THE ROLE OF PHARMACOTHERAPY IN THE TREATMENT OF PATIENTS WITH BORDERLINE PERSONALITY-DISORDER
    STONE, MH
    [J]. PSYCHOPHARMACOLOGY BULLETIN, 1989, 25 (04) : 564 - 571
  • [33] Integrated treatment for borderline personality disorder
    Oldham, John M.
    [J]. PSYCHIATRIC ANNALS, 2006, 36 (05) : 361 - +
  • [34] Psychopathology and treatment of borderline personality disorder
    Bohus, M.
    Schmahl, C.
    [J]. NERVENARZT, 2007, 78 (09): : 1069 - 1080
  • [35] Venlafaxine in the treatment of borderline personality disorder
    Markovitz, PJ
    Wagner, SC
    [J]. PSYCHOPHARMACOLOGY BULLETIN, 1995, 31 (04) : 773 - 777
  • [36] Treatment Advances in Borderline Personality Disorder
    Nelson, Katharine J.
    Schulz, S. Charles
    [J]. PSYCHIATRIC ANNALS, 2012, 42 (02) : 59 - 64
  • [37] Treatment of borderline personality disorder with risperidone
    Rocca, P
    Marchiaro, L
    Cocuzza, E
    Bogetto, F
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (03) : 241 - 244
  • [38] Treatment and prevention of borderline personality disorder
    Taubner, Svenja
    [J]. PSYCHOTHERAPEUT, 2020, 65 (05): : 329 - 330
  • [39] Fluoxetine in the treatment of borderline personality disorder
    Silva, H
    Jerez, S
    Paredes, A
    Salvo, J
    Renteria, P
    Ramirez, A
    Montes, C
    [J]. ACTAS LUSO-ESPANOLAS DE NEUROLOGIA PSIQUIATRIA Y CIENCIAS AFINES, 1997, 25 (06): : 391 - 395
  • [40] Quetiapine in the treatment of borderline personality disorder
    Hilger, E
    Barnas, C
    Kasper, S
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S329 - S329